Aditxt (ADTX) said Monday it will terminate its merger agreement with Appili Therapeutics, with plans of formal notification expected on May 31.
The company said the merger agreement had been amended several times to extend key milestones and accommodate changing circumstances.
"Despite these efforts, Aditxt has concluded that it is no longer strategically aligned to move forward under the terms of the agreement," it said.
Aditxt said the termination will eliminate about $16 million in closing obligations.
Shares of the company were up over 5% in recent trading.
Price: 1.76, Change: +0.10, Percent Change: +5.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.